BB-backed Ionis hit as FDA rejects Waylivra Shares in Ionis Pharmaceuticals (Nasdaq: IONS), a key shareholding for BB Biotech (10.9% of NAV) and several other specialist investment vehicles, fell by more than 12% after hours yesterday, after the FDA issued a complete response letter (CRL) – effectively a rejection – of its new drug application for Waylivra (volanesorsen). The […]
Standard Life UK Smaller Companies – outperformance, merger and lower fees – the NAV of Standard Life UK Smaller Companies (SLS) delivers a total return of 24.8%, compared with the total return of 8.5% of it’s reference index, the Numis Smaller Companies plus AIM (excluding Investment Companies) Index. Outperformance The company’s performance was good throughout the year in question with a particularly […]
Electra’s Formal Sales Process is closed – but the Strategic Review continues For sometime, Electra Private Equity (ELTA) has been conducting a strategic review on itself. The objective of the review has been to consider all options for the future direction of the company and to implement a strategy to optimise shareholder value. There had been two previous […]
Better Capital 2012 warns on Everest/SPOT – The Better Capital PCC Limited 2012 Cell has made an announcement about its end March NAV. Everest Valuation at 31 March 2018/SPOT Progress BECAP12 GP Limited, General Partner of BECAP12 Fund LP, has informed the board of Better Capital PCC Limited that: in the process of finalising the 2017 annual […]
Trust favourite Gilead gears up for filgotinib RA Phase III data Gilead Sciences, a widely held stock among biotech investment trusts and a top 10 holding for BB Biotech (BBB, 5.1% of NAV) and Biotech Growth Trust (BIOG, 3.9%), is expected to report top-line results from two trials involving its JAK 1 selective inhibitor filgotinib in rheumatoid arthritis (RA) and in ankylosing […]
WPCT takes profits on Autolus post IPO share price rise Woodford Patient Capital Trust (WPCT) appears to have taken some profits on its investment in the high-flying second generation CAR-T therapy company, Autolus Therapeutics, through a partial sale of its recently-boosted stake, according to an analysis of trust’s shareholdings in July reported this morning. This is […]
AbbVie exercises option for HBM-backed Argenx antibody Dutch/Belgian antibody company Argenx (Euronext & Nasdaq: ARGX), a top ten holding for Swiss-listed HBM Healthcare (HBMN, 2.6% of NAV) has disclosed that AbbVie has taken up its option to licence the preclinical stage immuno-oncology product ARGX-115. Argenx and AbbVie, a US based pharmaceutical major, entered into an option deal covering ARGX-115 in April […]
Schroder European Real Estate buys three industrial properties – Schroder European Real Estate Investment Trust has exchanged contracts to purchase three industrial assets in the Netherlands for a total purchase price of EUR19.8 million, reflecting a combined net initial yield of 6.5%, with a weighted unexpired lease term of approximately 9 years. In Venray, the Netherlands, Schroder […]
Oakley Capital investing in cPanel – Oakley Capital Investments Limited will invest in cPanel via the Oakley Funds. WebPros BV, the holding company that owns Plesk and Solus VM, and which Oakley Capital Private Equity III first invested in in April 2017 (when WebPros bought Plesk), is acquiring a majority stake in cPanel from its founder J. Nick […]
Hg Capital sells Kinapse – HgCapital Trust has announced the sale of Kinapse to Syneos Health, a leading biopharmaceutical solutions organisation. Kinapse is a market leading advisory and operational solutions provider to the global life sciences industry. The terms of the transaction were not disclosed. This transaction values the company’s investment in Kinapse at approximately GBP7.9 million. […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
